Abstract:Gefitinib is an orally potent and selective ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and is commonly used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations. Multiple adverse effects associated with gefitinib, including liver and lung injuries, severe nausea, and diarrhea, have limited its clinical application. Xenobiotic-induced bioactivation is thought to be an important reason for gefitinib toxicity, which encouraged us to clarify the metabolism of gefitinib in NSCLC patients.An ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry (UPLCQ-TOF-MS) method was established to tentatively identify the metabolites of gefitinib in human plasma. The extracted ion chromatogram peak intensity threshold was set at 1500 cps with minimum MS and MS/MS peak intensities of 400 and 100 cps, respectively.A total of 18 tentative metabolites were identified. Eight novel tentative metabolites with metabolic changes in dechlorination, defluorination, and hydrogenation on the quinazoline skeleton; removal of a partial or complete 3-chloro-4-fluoroaniline-substituted group; and sulfate conjugation and taurine conjugation were newly discovered in human plasma. Based on structural analysis of the tentative metabolites, the metabolic pathways were proposed. In addition, the pathways of dechlorination, defluorination, and hydrogenation on the quinazoline skeleton; removal of partial or complete 3-chloro-4-fluoroaniline-substituted groups; and sulfate conjugation and taurine conjugation in humans in vivo indicate that novel metabolic pathways exist in humans.In summary, the metabolism of gefitinib in humans in vivo is extensive and complex. Based on in vivo evidence, the propoxy-morpholine ring side chain and O-methyl group are the critical metabolic regions of gefitinib in humans. The novel metabolic pathways differ from those of in vitro studies, suggesting that intestinal floral metabolism might be involved.

Differential Metabolism of 3FDT and Docetaxel in RLMs, Rats, and HLMs.

Design, Synthesis and Biological Evaluation of Novel Fluorinated Docetaxel Analogues.

Synthesis, cytotoxicity, metabolic stability and pharmacokinetic evaluation of fluorinated docetaxel analogs.

Novel Fluorinated Docetaxel Analog for Anti-Hepatoma: Molecular Docking and Biological Evaluation.

Quantification of Antitumor Caffeic Acid-3,4-Dihydroxybenzylethyl Ester and Its Pharmacokinetic Study in Human Liver Microsomes by LC-MS/MS

Study on Cytochrome P450 Metabolic Profile of Paclitaxel on Rats using QTOF-MS

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Mitochondrial-targeted Prodrug Cancer Therapy Using a Rhodamine B Labeled Fluorinated Docetaxel

Mechanism of Tetrandrine in Combination with Droloxifen to Reverse Multidrug Resistance in Leukemia

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

INFLUENCE OF CYP3A5 AND MDR1 POLYMORPHISM ON THE PHARMACOKINETICS OF TACROLIMUS IN RESPONSE TO METABOLIC INHIBITION BY DILTIAZEM.

Metabonomic study on the antitumor effect of flavonoid derivative 3d in HepG2 cells and its action mechanism.

Study on tissue distribution, metabolite profiling, and excretion of [ 14 C]-labeled flonoltinib maleate in rats

Evaluation of fluorochloridone metabolism-dependent cytotoxicity with human liver microsome and mouse 3T3 cell system

Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry

Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

Differences in Fatty Acid Oxidation between Nab -Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics

Folate Acid-Cyclodextrin/docetaxel Induces Apoptosis in KB Cells Via the Intrinsic Mitochondrial Pathway and Displays Antitumor Activity in Vivo.

Metabolism and pharmacokinetic study of deuterated osimertinib

Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.